Adamax
10mg
❄️Lyophilized powder (not reconstituted)
Discount per Quantity
| Quantity | Discount | Price per Unit |
|---|---|---|
| 5 - 10 | 10% | €53.99 |
| 11 - 20 | 15% | €50.99 |
| 21+ | 20% | €47.99 |
Rigorous third-party testing
Every batch of our research chemicals and peptides undergoes independent third-party laboratory testing for purity and identity.
Total: €59.99
Adamax is a catalogue name used for a proposed adamantane-modified member of the Semax peptide family, supplied here in a nominal 10 mg presentation. Unlike Semax, Adamax does not currently have a well-established independent record in peer-reviewed primary literature or an authoritative chemical registry. The exact sequence, modification site, salt form, molecular mass and identity must therefore come from the approved product specification and matching batch CoA rather than from the name alone.
Identity and scientific context
| Catalogue name | Adamax |
| Material category | Semax-family designer research peptide |
| Proposed structural feature | An adamantane-containing modification associated with a Semax-family sequence; exact connectivity is batch-specific until documented |
| Authoritative formula or CAS number | Not assigned here because the catalogue name is used for inconsistent structures in secondary sources |
| Presentation | Nominal 10 mg catalogue vial |
Research background
The structural rationale commonly proposed for Adamax is that an adamantane-containing group could alter lipophilicity, proteolytic stability or distribution relative to an unmodified peptide. Those are testable chemical hypotheses, not established performance claims for this vial. Findings reported for Semax, ACTH fragments or other adamantane-containing compounds cannot be transferred automatically to Adamax.
Technical comparison
| Aspect | Adamax catalogue material | Semax reference material |
|---|---|---|
| Identity | Must be defined by the exact documented sequence and adamantane-containing modification | Can be defined by a specified Semax sequence, termini and salt form |
| Evidence base | Independent primary evidence is currently very limited | Semax has a separate published literature that does not validate Adamax |
| Analytical priority | Confirm intact mass, sequence, modification site, purity, counter-ion and vial content | Confirm the specified Semax entity and matching batch attributes |
Quality, handling and storage
Use only analytical results linked to the exact lot and presentation. Chromatographic area purity does not by itself confirm sequence, modification position, net peptide content, sterility or endotoxin status. Until the matching specification and CoA define the material, formulae and identifiers quoted by unrelated vendors should not be treated as product facts.
Store and handle the vial under the conditions on its label and matching SDS. Keep it secured, clearly identified and protected from moisture, light and contamination as directed by the batch documentation.
Frequently Asked Questions
Is Adamax simply a stronger form of Semax?
No such conclusion is established. The proposed modification changes the chemical entity, and comparative activity must be demonstrated directly with well-characterised materials.
Why is no CAS number shown?
The name “Adamax” is used inconsistently across secondary sources. A registry identifier should be displayed only when it matches the exact structure and material form confirmed for the batch.
Regulatory notice
Adamax is offered as a catalogue research material for qualified professionals and is not an authorised medicinal product.